Aryl-and heteroaryl-thiosemicarbazone derivatives and their metal complexes: A pharmacological template

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 2, 2013, Pages 168-182

  Moorthy, Narayana S H N ^a   Cerqueira, Nuno M F S A ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cancer; DNA; Isatin; Ribonucleotide reductase; Thiosemicarbazones

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; BENZOYL PYRIDYLTHIOSEMICARBAZONE DERIVATIVE; BISPYRIDYL THIOSEMICARBAZONE DERIVATIVE; COBALT; COPPER; DNA TOPOISOMERASE (ATP HYDROLYSING); HYDRAZONE DERIVATIVE; IRON; ISATIN THIOSEMICARBAZONE DERIVATIVE; METAL COMPLEX; METAL ION; METISAZONE; NICKEL; NSC 658339; NSC 716765; NSC 716766; NSC 716768; NSC 716771; NSC 716772; NSC 73306; PALLADIUM; PLATINUM; PYRIDOXAL THIOBENZOYL HYDRAZONE; PYRIDYL THIOSEMICARBAZONE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; SALICYLALDEHYDE THIOBENZOYL HYDRAZONE; THIOHYDRAZONE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BODY FLUID; CHELATION; COMPLEX FORMATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MOLECULAR INTERACTION; NONHUMAN; PATENT; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTIGENS, NEOPLASM; COORDINATION COMPLEXES; DELAYED-ACTION PREPARATIONS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PATENTS AS TOPIC; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES;

EID: 84875300425     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489213805290583     Document Type: Review

References (154)

1. Bavin EM, Rees RJW, Robson JM, Seiler M, Seymour DE, Suddaby D. The tuberculostatic activity of some thiosemicarbazones. J Pharm Pharmacol 1950; 2: 764-72.
2. Koch O, Stuttgen G. Clinical and experimental studies on the effects of thiosemicarbazones. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1950; 210: 409-23.
3. Pelosi G. Thiosemicarbazone metal complexes: From structure to activity. The Open Crystallograph J 2010; 3: 16-28.
4. Brockman RW, Thomson JR, Bell MJ, Skipper HE. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 1956; 16: 167-70.
5. Levinson W, Faras A, Woodson B, Jackson J, Bishop JM. Inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus by thiosemicarbazones and several cations. Proc Natl Acad Sci USA 1973; 70: 164-8.
6. Bauer DJ. A history of the discovery and clinical application of antiviral drugs. Br Med Bull 1985; 41: 309-14.
7. Beraldo H, Gambino D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini Rev Med Chem 2004; 4: 31-9.
8. Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, et al. Synthesis, activity, and pharmacophore development for isatin-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem 2009; 52: 3191-204.
9. French FA, Blanz EJJ. The carcinostatic activity of alpha-(N) heterocyclic carboxaldehyde thiosemicarbazones. I. Isoquinoline-1-carboxaldehyde thiosemicarbazone. Cancer Res 1965; 25: 1454-8.
10. Hards RG, Wright JA. N-Carbamoyloxyurea-resistant Chinese hamster ovary cells with elevated levels of ribonucleotide reductase activity. J Cell Physiol 1981; 106: 309-19.
11. Cameron IL, Jeter JR. Action of hydroxyurea and N-carbamoyloxyurea on the cell cycle of tetrahymena. Cell Proliferat 1973; 6: 289-01.
12. rd ed. Wiley: New York 1985.
13. Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, et al. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 2009; 20: 1275-9.
14. Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, et al. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 2008; 26: 169-73.
15. Niu, C.S., Li, J., Li, X., Doyle, T.W., Chem, S.H. Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP. WO98051670 (1998).
16. Antholine W, Knight J, Whelan H, Petering DH. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol Pharmacol 1977; 13: 89-98.
17. Finch RA, Liu M-C, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enz Regul 1999; 39: 3-12.
18. Dean RT, Nicholson P. The action of nine chelators on iron dependent radical damage. Free Radical Res 1994; 20: 83-101.
19. Richardson, D.R., Lovejoy, D.B. Metal ion chelators and therapeutic use thereof. EP1608623 (2011).
20. Pillai CK, Nandi US, Levinson W. Interaction of DNA with anticancer drugs: Copper-thiosemicarbazide system. Bioinorg Chem 1977; 7: 151-7.
21. Kumar GDK, Chavarria GE, Charlton-Sevcik AK, Arispe WM, MacDonough MT, Strecker TE, et al. Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett 2010; 20: 1415-9.
22. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 86: 4295-306.
23. Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004; 4: 1623-35.
24. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, et al. Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 2009; 52: 5271-94.
25. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006; 103(40): 14901-6.
26. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003; 63: 1731-6.
27. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao Y-T, Lovejoy DB, et al. Design, synthesis and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogs as potent anti-tumor agents. J Med Chem 2007; 50: 3716-29.
28. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, et al. Dipyridyl thiosemicarbazone chelators with potent and selective anti-tumor activity form iron complexes with marked redox activity. J Med Chem 2006; 49: 6510-21.
29. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood 2004; 104: 1450-8.
30. Opletalova V, Kalinowski DS, Vejsova M, Kunes J, Pour M, Jampi{dotless}lek J, et al. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: Cellular iron chelation mediating cytotoxic activity. Chem Res Toxicol 2008; 21: 1878-89.
31. De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: Consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008; 9: 72-81.
32. Park J, Sung ND. 3D-QSAR analysis and molecular docking of thiosemicarbazone analogues as a potent tyrosinase inhibitor. Bull Korean Chem Soc 2011; 32: 1241-8.
33. Lovejoy DB. Richardson DR. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002; 100: 666-76.
34. Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol 2003; 138: 819-30.
35. Agarwal RP, Perrin DD. Computer-based approach to chelation therapy: A theoretical study of some chelating agents for the selective removal of toxic metal ions from plasma. Agents Actions 1976; 6: 667-73.
36. Hasinoff BB, Patel D. The iron chelator Dp44mT does not protect myocytes against doxorubicin. J Inorg Biochem 2003; 103: 1093-101.
37. Bull C, McClune GJ, Fee JA. The mechanism of iron EDTA catalyzed superoxide dismutation. J Am Chem Soc 1983; 105: 5290-300.
38. Qian SY, Buettner GR. Iron and dioxygen chemistry is an important route to initiation of biological free radical oxidations: An electron paramagnetic resonance spin trapping study. Free Radic Biol Med 1999; 26: 1447-56.
39. Jansson PJ, Hawkins CL, Lovejoy DB, Richardson DR. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study. J Inorg Biochem 2010; 104: 1224-8.
40. Richardson, D.R., Lovejoy, D.B. Metal ion chelators and therapeutic use thereof. WO2004069801 (2004).
41. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 2009; 84: 170-6.
42. Rao AV, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, Shacter EB. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIA in breast cancer cells. Cancer Res 2009; 69(3): 948-57.
43. Miao Q, Xu D, Wang Z, Xu L, Wang T, Wua Y, et al. Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials 2010; 31: 7364-75.
44. Richardson, D.R., Lovejoy, D.B. Thiosemicarbazone compounds and use thereof. WO2010000008 (2010).
45. Aguirre MJ, Isaacs M, Armijo F, Basaez L, Zagal JH. Effect of the substituents on the ligand of iron phthalocyanines adsorbed on graphite electrodes on their activity for the electrooxidation of 2-mercaptoethanol. Electroanalysis 2002; 14: 356-62.
46. Chambers J, Eaves B, Parker D, Claxton R, Ray PS, Slattery SJ. Inductive influence of 4¢-terpyridyl substituents on redox and spin state properties of iron(II) and cobalt(II) bis-terpyridyl complexes. Inorg Chim Acta 2006; 359: 2400-6.
47. Lanznaster M, Neves A, Bortoluzzi AJ, Assumpcao AMC, Vencato I. Electronic effects of electron-donating and-withdrawing groups in model complexes for iron-tyrosine-containing metalloenzymes. Inorg Chem 2006; 45: 1005-11.
48. Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, et al. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: Redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 2009; 52: 1459-70.
49. Enyedy EA, Nagy NV, Zsigo E, Kowol CR, Arion VB, Keppler BK, et al. Comparative solution equilibrium study of the interactions of copper(II), iron(II) and zinc(II) with Triapine (3-aminopyridine-2-carbaldehyde thiosemicarbazone) and related ligands. Eur J Inorg Chem 2010; 11: 1717-28.
50. Enyedy EA, Primik MF, Kowol CR, Arion VB, Kiss T, Keppler BK. Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): A comparative solution equilibrium study. Dalton Trans 2011; 40: 5895-905.
51. Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, et al. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 2006; 5(3): 586-92.
52. Nyholm S, Thelander L, Graslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 1993; 32: 11569-74.
53. Thelander L, Graslund A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone: Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J Biol Chem 1983; 258: 4063-66.
54. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of Triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003; 9: 402-14.
55. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Gräslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993; 268: 26200-5.
56. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004; 22(9): 1553-63.
57. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000; 59: 983-91.
58. Chen C-H, King I, Belcourt M. Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytotoxicity to KB cells. Eur J Cancer 2002; 38: S26-7.
59. Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Cur Opin Drug Discov Devel 2009; 12(2): 246-52.
60. Developmental Therapeutics Program, National Cancer Institute. Available at: http:// dtp.nci.nih.gov. (Accessed on: July 30, 2012).
61. Levinson W, Faras A, Woodson B, Jackson J, Bishop JM. Inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus by thiosemicarbazones and several cations. Proc Natl Acad Sci USA 1973; 70: 164-8.
62. Moorthy NSHN, Karthikeyan C, Trivedi P. Design, synthesis, cytotoxic evaluation and QSAR study of some 6H-indolo [2,3-b]quinoxaline derivatives. J Enz Inhibit Med Chem 2010; 25(3): 394-405.
63. Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, et al. Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 2009; 69: 8293-301.
64. Ludwig JA, Szakacs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006; 66(9): 4808-15.
65. Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: A potent substrate of the multidrug resistancelinked ABCG2 transporter. Mol Cancer Ther 2007; 6(12): 3287-96.
66. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: Desferrioxamine to Triapine and beyond. Clin Cancer Res 2006; 12: 6876-83.
67. Sebastian L, Desai A, Shampur MN, Perumal Y, Sriram D, Vasanthapuram R. N-Methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virol J 2008; 5: 64-76.
68. Alexacou KM, Tenchiu (Deleanu) AC, Chrysina ED, Charavgi MD, Kostas ID, Zographos SE, et al. The binding of α-Dglucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors. Bioorg Med Chem 2010; 18: 7911-22.
69. Aiston S, Andersen B, Agius L. Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase. Diabetes 2003; 52: 1333-9.
70. Aiston S, Coghlan MP, Agius L. Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. Eur J Biochem 2003; 270: 2773-81.
71. Oikonomakos NG. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr Protein Pept Sci 2002; 3: 561-86.
72. Wnag, Y., Cai, X., Keana, F.W. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof. US20020061886 (2002).
73. Wnag, Y., Cai, X., Lan, N.C., Keana, J.F.W., Ilyin, V.I. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof. US20020813321 (2002).
74. Vieites M, Otero L, Santos D, Olea-Azar C, Norambuena E, Aguirre G, et al. Platinum-based complexes of bioactive 3-(5-nitrofuryl) acroleine thiosemicarbazones showing anti-Trypanosoma cruzi activity. J Inorg Biochem 2009; 103: 411-8.
75. Otero L, Maya JD, Morello A, Rigol C, Barriga G, Rodríguez J, et al. Insight into the bioreductive mode of action of antitrypanosomal 5-nitrofuryl containing thiosemicarbazones. Med Chem 2008; 4: 11-7.
76. Matesanz AI, Joie C, Souza P. Chemistry, antiproliferative activity and low nephrotoxicity of 3,5-diacetyl-1,2,4-triazol bis(4Nthiosemicarbazone) ligands and their platinum(II) complexes. Dalton Trans 2010; 39: 7059-65.
77. Millan, R.D.S., Coelho, M.M., Vieria, R.P., Teixeira, L.R.S., Doreto, M.S., Beraldo, H.O., Andrade, S.P. Pharmaceutical composition of semicarbazones and /or thiosemicarbazones and /or their derivatives and products of these compositions and their uses as anticonvulsant, antinociceptive, and anti-inflammatory agents and in the angiogenic therapy. US20080058284 (2008).
78. Sinisterra, R.D., Coelho, M.D.M., Doretto, M.C., Vieira, R.P., Teixeira, L.R.D.S., Beraldo, H.D.O. Process to prepare semicarbazones and/or thiosemicarbazones formulations using cyclodextrins and their derivatives and products obtained by this process. WO0303066038 (2003).
79. Sinisterra, R.D., Coelho, M.D.M., Beraldo, H.D.O., Doretto, M.C., Vieira, R.P., Teixeira, L.R.D.S., Andrade, S.P. Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation. US20100249238 (2010).
80. Revenko MD, Gerbeleu NV, Indrichan KM. Demetalation of nickel coordination compounds with tetradentate ligands derived from Ssubstituted isothiosemicarbazides. Teoreticheskayai Eksperimental'naya Khimiya 1985; 21: 604-8.
81. Gerbeleu NV, Turta KI, Canic VM, Arion VB. Iron(III) complexes of salicylaldehyde S-methylisothiosemicarbazone. Koord Khim 1980; 6: 446-50.
82. Atasever B, Ulkuseven B, Bal-Demirci T, Erdem-Kuruca S, Solakoglu Z. Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells. Invest New Drugs 2010; 28(4): 421-32.
83. Belicchi-Ferrari M, Bisceglie F, Pelosi G, Tarasconi P. Heterocyclic substituted thiosemicarbazones and their Cu(II) complexes: Synthesis, characterization and studies of substituent effects on coordination and DNA binding. Polyhedron 2008; 27: 1362-7.
84. Barsanti, P.A., Brammeier, N., Diebes, A., Lagniton, L.M., Ng, S., Ni, Z.-J., Pfister, K.B., Philbin, C., Valiante, N., Wagman, A.S., Wang, W., Weiner, A.J. Thiosemicarbazones as antivirals and immunopotentiators. US7521062 (2009).
85. Alonso R, Bermejo E, Carballo R, Castineiras A, Perez T. The supramolecular chemistry of thiosemicarbazones derived from pyrrole: A structural view. J Mol Struct 2002; 606: 155-73.
86. Janiak C. A critical account on π-π stacking in metal complexes with aromatic nitrogen-containing ligands. J Chem Soc Dalton Trans 2000; 3885-96.
87. Desiraju GR. Supramolecular synthons in crystal engineering-A new organic synthesis. Angew Chem Int Ed Engl 1995; 34: 2311-27.
88. Cai L, Li XK, Song Y, Cherian MG. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 2005; 12: 2753-63.
89. Pandeya SN, Sriram D, Nath G, DeClercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4-chlorophenyl) thiazol-2-yl] thiosemicarbazide. Eur J Pharm Sci 1999; 9: 25-31.
90. DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Bertino JR, et al. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 1972; 32: 1455-62.
91. French FA, Blanz EJ. Jr. The carcinostatic activity of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. II. 3-Hydroxypyridine-2-carboxaldehyde thiosemicarbazone. Cancer Res 1966; 26: 1638-40.
92. Kowol CR, Berger R, Eichinger R, Roller A, Jakupec MA, Schmidt PP, et al. Gallium(III) and iron(III) complexes of R-N-heterocyclic thiosemicarbazones: Synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem 2007; 50: 1254-65.
93. Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, et al. A ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 2006; 5: 586-92.
94. Kowol CR, Trondl R, Heffeter P, Arion VB, Jakupec MA, Roller A, et al. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thio/semicarbazone (Triapine) and novel insights into terminal dimethylation. J Med Chem 2009; 52: 5032-43.
95. Horton D, Varela O. Cu, Pt, and Pd complexes of the 3-deoxy-1,2-bis(thiosemicarbazone) derived from D-glucose. Carbohydr Res 2000; 328: 425-9.
96. Genova P, Varadinova T, Matesanz AI, Marinova D, Souza P. Toxic effects of bis(thiosemicarbazone) compounds and its palladium(II) complexes on herpes simplex virus growth. Toxicol Appl Pharmacol 2004; 197: 107-12.
97. Pelosi G, Bisceglie F, Bignami F, Ronzi P, Schiavone P, Re MC, et al. Antiretroviral activity of thiosemicarbazone metal complexes. J Med Chem 2010; 53: 8765-9.
98. Rosu T, Gulea A, Nicolae A, Georgescu R. Complexes of 3dn metal ions with thiosemicarbazones: Synthesis and antimicrobial activity. Molecules 2007; 12: 782-96.
99. Ferrari MB, Fava GG, Tarasconi P, Pelizzi C. Thiosemicarbazones as co-ordinating agents. Part 3. Synthesis, spectroscopic characterization, and X-ray structure of methyl pyruvate thiosemicarbazone hemihydrate, chloro(ethyl pyruvate thiosemicarbazonato)copper(II) (green form), and chloro(pyruvic acid thiosemicarbazonato) copper(II) dihydrate (blue form). J Chem Soc Dalton Trans 1989; 2: 361-6.
100. Lobana TS, Sharma R, Bawa G, Khanna S. Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview. Coordination Chem Rev 2009; 253: 977-1055.
101. Leovac VM, Bogdanović GA, Jovanović LS, Joksović L, Marković V, Joksović MD, et al. Synthesis, characterization and antitumor activity of polymeric copper(II) complexes with thiosemicarbazones of 3-methyl-5-oxo-1-phenyl-3-pyrazolin-4-carboxaldehyde and 5-oxo-3-phenyl-3-pyrazolin-4-carboxaldehyde. J Inorg Biochem 2011; 105: 1413-21.
102. Petrovic DM, Petrovic AE, Leovac VM, Lukic SR. Decomposition of Cu(II) complex with salicylaldehyde S-methyl thiosemicarbazone. J Thermal Anal 1994; 41: 1165-70.
103. Leovac V, Vojinovi LS, Szécsényi K, Eljevi VI. Transition metal complexes with thiosemicarbazide-based ligands. Part 46. Synthesis and physico-chemical characterization of mixed ligand cobalt(III)-complexes with salicylaldehyde semi-, thiosemi-and isothiosemicarbazone and pyridine. J Serb Chem Soc 2003; 68(12): 919-27.
104. Bahr G, Schleitzer EZ. Über emprotide Schwermetall-Innerkomplexe der α-Diketondithiosemicarbazone (Thiazone). III. Anorg Allg Chem 1955; 278: 136-54.
105. Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-activity relationships. J Biol Inorg Chem 2002; 7: 249-59.
106. Castle TC, Maurer RI, Sowrey FE, Went MJ, Reynolds CA, McInnes EJL, et al. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: Comparison with their sulfur analogues. J Am Chem Soc 2003; 125: 10040-9.
107. Fonteh PN, Keter FK, Meyer D. New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: Potential for incorporation into virostatic cocktails. J Inorg Biochem 2011; 105: 1173-80.
108. 2(tmen)] compound. Polyhedron 2008; 27: 440-6.
109. Revenco MD, Simonov YA, Duca GG, Bourosh PN, Bulmaga PI, Kukushkin Y, et al. Versatility and reactivity of salicylaldehyde S methylisothiosemicarbazone in palladium(II) complexes. Zhurnal Neorganicheskoi Khimii 2009; 54(5): 756-65.
110. Revenco MD, Palamarciuc OV, Bourosh PV, Lipkowski J, Gdaniec M, Simonov YA, et al. New template reactions of salicylaldehyde S-methyl-isothiosemicarbazone with 2-formylpyridine promoted by Ni(II) or Cu(II) metal ions. Inorg Chimica Acta 2011; 368: 157-64.
111. Gerasimov VI, Revenko MD, Biyushkin VN, Golyshev VM, Gerbeleu NV, Belov NV. X-ray structural study of coordination copper(II) compound with S-methylthiosemicarbazone of salicylic aldehyde. Kristallografiya 1976; 21(2): 399-402.
112. Gerbeleu NV, Arion VB, Indrichan KM. Template synthesis and investigations of nickel coordinated compounds with bis-(S-alkylthiosemicarbazones and S-benzyl-thiosemicarbazones)2,4-pentadione and 3-oxo-2,4-pentandione. Zhurnal Neorganicheskoi Khimii 1985; 30(11): 2833-7.
113. Vedyanu AN, Gerbeleu NV. Coordination-compounds of nickel and cobalt(II) thiocyanates and selenocyanates with thiosemicarbazones and selenosemicarbazones. Zhurnal Neorganicheskoi Khimii 1976; 21(12): 3319-23.
114. Ferrari MB, Bisceglie F, Pelosi G, Tarasconi P, Albertini R, Bonati A, et al. Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes. J Inorg Biochem 2001; 83: 169-79.
115. Pal I, Basuli F, Bhattacharya S. Thiosemicarbazone complexes of the platinum metals. A story of variable coordination modes. Proc Indian Acad Sci (Chem Sci) 2002; 114(4): 255-68.
116. Popović-Bijelić A, Kowol CR, Lind MES, Luo J, Himo F, Enyedy EA, et al. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): A combined experimental and theoretical study. J Inorg Biochem 2011; 105: 1422-31.
117. Kalinowski DS, Sharpe PC, Bernhardt PV, Richardson DR. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: Structure-activity relationships of novel thiohydrazone analogues. J Med Chem 2007; 50: 6212-25.
118. Seto CT, Mathias JP, Whitesides GM. Molecular self-assembly through hydrogen bonding: Aggregation of five molecules to form a discrete supramolecular structure. J Am Chem Soc 1993; 115: 1321-9.
119. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57: 547-83.
120. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603: 31-46.
121. Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 2002; 42: 267-81.
122. Krishnan K, Prathiba K, Jayaprakash V, Basu A, Nibha M, Zhou B, et al. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones. Bioorg Med Chem Lett 2008; 18: 6248-50.
123. Easmon J, Purstinger G, Thies KS, Heinisch G, Hofmann J. Synthesis, structure-activity relationship and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroatoms. J Med Chem 2006; 49: 6343-50.
124. Davis, M.E., Heidel, J.D., Rossi, J.J. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof. US7427605 (2008).
125. Easmon J, Heinisch G, Hofmann J, Langer T, Grunicke HH, Fink J, et al. Thiazolyl and benzothiazolyl hydrazones derived from R-(N)-acetylpyridines and diazines: Synthesis, antiproliferative activity and CoMFA studies. Eur J Med Chem 1997; 32: 397-408.
126. Agrawal KC, Sartorelli AC. The chemistry and biological activity of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 1978; 15: 321-56.
127. Yu Y, Rahmanto YS, Hawkins CL, Richardson DR. The potent and novel thiosemicarbazone chelators, Dp44mT and Bp44mT, affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol 2011; 79: 921-31.
128. Avval FZ, Holmgren A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J Biol Chem 2009; 284(13): 8233-40.
129. Jansson PJ, Sharpe PC, Bernhardt PV, Richardson DR. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: Identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 2010; 53(15): 5759-69.
130. Heffeter P, Pirker C, Kowol CR, Herrman G, Dornetshuber R, Miklos W, et al. Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones. Biochem Pharmacol 2012; 83(12): 1623-33.
131. Cerqueira NMFSA, Fernandes PA, Ramos MJ. Ribonucleotide reductase: A critical enzyme for cancer chemotherapy and antiviral agents. Recent Patents Anticancer Drug Discov 2007; 2: 11-29.
132. Pereira S, Cerqueira NM, Fernandes PA, Ramos MJ. Computational studies on class I ribonucleotide reductase: Understanding the mechanisms of action and inhibition of a cornerstone enzyme for the treatment of cancer. Eur Biophys J 2006; 35: 125-35.
133. Moorthy NSHN, Cerqueira NMFS, Ramos MJ, Fernandes PA. QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors. Med Chem Res 2012; 21: 739-46.
134. Moorthy NSHN, Cerqueira NMFS, Ramos MJ, Fernandes PA. QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction. Med Chem Res 2012; 21: 133-44.
135. Moorthy NSHN, Ramos MJ, Fernandes PA. Pharmacophore based screening and QSAR analysis of structurally diverse compounds for lead selection and optimization against multiple targets. Open-Tox Interaction Meeting on Innovation in Predictive Toxicology, Munich, Germany, August 10-12, 2011.
136. Moorthy NSHN, Cerqueira NMFS, Ramos MJ, Fernandes PA. Thiosemicarbazone derivatives as potent RNR inhibitors: In silico based pharmacophore, binding mode and toxicity analysis. Moscow Conference on Computational Molecular Biology (MCCMB' 11), Moscow, Russian Federation, July 21-24, 2011.
137. Cerqueira NMFSA, Fernandes PA, Ramos MJ, Eriksson LA. Ribonucleotide activation by enzyme ribonucleotide reductase: Understanding the role of the enzyme. J Comput Chem 2004; 25: 2031-37.
138. Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 1987; 27: 21-35.
139. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine ® in patients with metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 2007; 25: 471-7.
140. Saumni AM, Krishna MC, Degraff W, Russo A, Planalp RP, Brechbiel MW, et al. Mechanism underlying the cytotoxic effects of Tachpyr-a novel metal chelator. Biochim Biophy Acta 2002; 1571: 211-8.
141. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planalp RP. Tumor cell cytotoxicity of a metal chelator. Blood 1998; 92: 1384-9.
142. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Rahmanto YS, Sharpe PC, et al. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Topics Med Chem 2011; 11(5): 483-99.
143. Kalinowski DS, Quach P, Richardson DR. Thiosemicarbazones: The new wave in cancer treatment. Future Med Chem 2009; 1(6): 1143-51.
144. Huang H, Chen Q, Ku X, Meng L, Lin L, Wang X, et al. A series of α-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIα catalytic activity. J Med Chem 2010; 53: 3048-64.
145. Lim S, Paterson BM, Fodero-Tavoletti MT, O'Keefe GJ, Cappai R, Barnham KJ, et al. A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: A bis(thiosemicarbazonato) copper(II) complex that binds to amyloid-beta plaques. Chem Commun (Camb) 2010; 46(30): 5437-9.
146. Patersonab BM, Donnelly PS. Copper complexes of bis(thiosemicarbazones): From chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals. Chem Soc Rev 2011; 40: 3005-18.
147. Fodero-Tavoletti MT, Villemagne VL, Paterson BM, White AR, Li QX, Camakaris J, et al. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J Alzheimers Dis 2010; 20(1): 49-55.
148. Dilworth, J.R., Peach, J.M., Heslop, J.M., Donnelly, S.P. Compounds for imaging and therapy. US20110098353 (2011).
149. Tofilon, P., Camphausen, K., Gius, D. Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents. US20090298891 (2009).
150. Danter, W.R. Inhibitor compounds and cancer treatment methods. US20100015140 (2010).
151. Danter, W.R., Lau, C.K. Compounds and method for treatment of cancer. US20110152281 (2011).
152. Donnelly, P.S., Paterson, B.M. Process for the preparation of asymmetrical bis(thiosemicarbazones). US20110305632 (2011).
153. Yen, Y., Horne, D., Yuan, Y.C., Zhou, B.S., Harki, A.L.P., Su, L. Ribonucleotide reductase inhibitors and methods of use. US20110245304 (2011).
154. Brown, A.V., Crouse, G.D., Sparks, T.C., Mcleod, C.L., Rigsbee, E.M., Lambert, W.T., Niyaz, N.M. Pesticidal compositions. US20120172217 (2012).